FORT MYERS, Fla., Jan. 31, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) this week celebrated the opening of a new state-of-the-art facility at 750 Orienta Ave.,Altamonte Springs, FL 32701-5621 serving adults with cancer, blood disorders and other diseases. "Our four FCS sites in Seminole County represent our commitment to ensuring that patients have convenient access to a comprehensive range of world-class cancer care and services close to home," said FCS Chief

Nine early career scientists awarded grants covering basic and translational liver disease research FAIRFIELD, N.J., Jan. 31, 2025 /PRNewswire/ -- American Liver Foundation (ALF) is thrilled to announce the recipients of its prestigious 2024 Liver Scholar and Postdoctoral Research Fellowship Awards. These awards are part of ALF's continued commitment to fund groundbreaking liver research and support early-career scientists dedicated to better understanding the biology of the healthy liver, disco

MARBURG, Germany, Jan. 31, 2025 /PRNewswire/ -- DRG Instruments GmbH ("DRG") has been a top developer and manufacturer of immunoassays for over 50 years. The company is creating a new division, DRG Neuroscience, and the new division is presenting on the market its fully automated CLIA tests for evaluating suspected Traumatic Brain Injury (TBI) - the GFAP and UCH-L1 combo Tests. These tests are designed for use on DRG's automated CLIA platform, DxDATA™, enabling the measurement of GFAP and UCH

Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share Related to 2024 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of $56.334 Billion, an Increase of 3.7 Percent on a Reported Basis and 4.6 Percent on an Operational Basis Full-Year Global Net Revenues from the Immunology Portfolio Were $26.682 Billion, an Increase of 2.1

Crown offer of $3.65 per share is the only offer available to Revance stockholders Crown offer unanimously approved by the Revance Board of Directors Teoxane withdraws its previous proposal, says it will tender its 6.2% stake in Revance into Crown tender Tender offer expires at one minute past 11:59 p.m., Eastern Time, on February 4, 2025 JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Jan. 31, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) (

ZURICH and NESS ZIONA, Israel, Jan. 31, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. ("Kadimastem") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure

STOCKHOLM, Jan. 31, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two additional questions. These questions will now be discussed at the CHMP meeting in February 2025, before the Commission can take a final decision on the Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease in the European Uni

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on January 30, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the IDEAYA Biosci

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Applied Therapeutics investors who were adversely affected by alleged securities fraud between January 3, 2024 and December 2, 2024. Follow the link below to get more information and be contacted by a member of our team: APLT

LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series TO 2. As of 31 January 2025, the registered number of shares and votes in Immunovia amounts to 261,908,863. For further information, please contact Jeff Borcherding, CEO [email protected] Karin Almqvist Liwendahl, CFO [email protected] +46 70 911 56 08 This information is such information that Immunovia A